Restricted accessResearch articleFirst published online 1996-11
Early Results of the Value of p53 in Predicting Survival in a Homogeneous Cohort of Patients with Invasive Bladder Cancer Treated with a Neoadjuvant Carboplatin-Based Regimen (M-CAVI)
Several reports on prognostic factors for infiltrating bladder cancer have given controversial results. We assessed the prognostic value of p53 nuclear overexpression together with known prognostic factors for survival in patients with invasive T2-4 NO MO bladder cancer treated with neoadjuvant chemotherapy.
Study Design
Thirty-five paraffi-nized tumor samples from initial transurethral resection of patients with bladder cancer were analyzed immunohistochemi-cally to detect overexpression of p53 protein. Patients were treated with 3 to 4 cycles of neoadjuvant methotrexate, carboplatin, and vinblastine (M-CAVI) and then underwent radical cystectomy. Prechemotherapy, treatment, and postchemotherapy factors were analyzed for correlation with survival by univariate and multivariate analysis. Fifty-seven percent of tumors were positive for p53 protein, 71.5% had grade III-IV tumors, and 72% had organ-confined disease. The median follow-up was 20 months (range 5-71+).
Results
By univariate analysis, the significant pretreatment factors were initial tumor (T) stage (P <0.0001) and the male sex (P = 0.03). Five postchemotherapy variables were found significant: surgery performed according to protocol (P = 0.003), overall clinical (P = 0.004), and overall pathologic (P = 0.02) response to therapy, postchemotherapy pathologic stage (P = 0.0002), and tumor status after surgery (P = 0.0006). By multivariate analysis, the initial prechemotherapy T stage was the only factor that demonstrated independent significance.
Conclusions
Although the median follow-up of the study is still too short, in this group of patients treated with a neoadjuvant carboplatin-based regimen, a classical variable (prechemotherapy T stage) rather than p53 nuclear overexpression was an independent prognostic factor for survival. Further follow-up will be required to assess the value of p53 overexpression as a prognostic factor in invasive bladder cancer patients treated with neoadjuvant carboplatin-based chemotherapy.
AllredD.C., ClarkG.M., TandonA.K., MolinaR., TormeyD.C., OsborneC.K., GilchristK.W., MansourE.G., AbeloffM., EudeyL., McGuireW.L.: HER2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.J. Clin. Oncol., 10: 599–605, 1992.
2.
BadalamentR.A.: (Editorial) Transitional cell carcinoma: a common sense approach.J. Urol., 153: 61–62, 1995.
3.
BanksL., MatlashewskiG., CrawfordL.: Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression.Eur. J. Biochem., 159: 529–534, 1986.
4.
BellmuntJ., AlbanellJ., GallegoO.S., RibasA., VicenteP., CarullaJ., De TorresJ.A., MoroteJ., LopezM., SoléL.A.: Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy.Cancer, 70: 1974–1979, 1992.
5.
BellmuntJ., RibasA., AlbanellJ., De TorresI., BermejoB., De TorresJ.A., MoroteJ., López-PaciosM.A., Banús GassolJ.M., CasadoS., CarullaJ., SoléL.A.: M-CAVI: a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder.Am. J. Clin. Oncol., 19: 344–348, 1996.
6.
BergkvistA., LjunguistA., MobergerG.: Classification of bladder tumors based on the cellular pattern.Acta Chir. Scand., 130: 371–378, 1965.
7.
CalvertA.H., NewellD.R., GrumbellL.A., O'ReillyS., Bru-nellM.C., BoxallF.E., SiddikA.H., JudsonI.R., GoreM.E., WiltshawE.: Carboplatin dosage: prospective evaluation of a simple formula based on renal function.J. Clin. Oncol., 7: 1748–1756, 1989.
8.
Cordon-CardoC., DalbagniG., SaezG.R., OlivaM.R., ZhangZ.F., RosaiJ., ReuterV.E., PellicerA.: p53 mutations in human bladder cancer: genotypic versus phenotipic patterns.Int. J. Cancer., 56: 347–353, 1994.
EsrigD., ElmajianD., GroshenS., FreemanJ.A., SteinJ.P., ChenS.C., NicholsP.W., SkinnerD.G., JonesP.A., CoteR.J.: Accumulation of nuclear p53 and tumor progression in bladder cancer.N. Engl. J. Med., 331: 1259–1264, 1994.
11.
EsrigD., SpruchC.H., NicholsP.W., ChaiwunB., StevenK., GroshenS., ChenS.C., SkinnerD.G., JonesP.A., CoteR.J.: p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.Am. J. Pathol., 143: 1389–1397, 1993.
12.
FossaS.D., BrenerA.A., JacobsenA-B., WaehreH., Kvar-steinB., UrnesT., OgreidP., Bjerklund JohansenT.E., SlideJ., NeslandJ.M., PettersenE.O.: Clinical significance of DNA ploidy and S-phase fraction and their relation to p53 protein, c-erbB-2 protein and HCG in operable muscle-invasive bladder cancer.Br. J. Cancer, 68: 572–578, 1993.
13.
FujimotoK., YamadaY., OkajimaE., KakizoeT., SasakiH., SugimuraT., TeradaM.: Frequent association of p53 gene mutation in invasive bladder cancer.Cancer Res., 52: 1393–1398, 1992.
14.
FurihataM., InoueK., OhtsukiY., HashimotoH., TeraoN., FujitaY.: High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder.Cancer Res., 53: 4823–4827, 1993.
HarrisA.L.: Mutant p53. The commonest genetic abnormality in human cancer? J.Pathol., 162: 5–6, 1990.
17.
LipponenP.K.: Expression of nuclear oncoprotein p53 in transitional cell bladder cancer and its prognostic value.Int. J. Cancer, 53: 365–370. 1993.
18.
LipponenP., EskelinenM.: Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis.Br. J. Cancer, 69: 1120–1125, 1994.
19.
MochH., SauterG., MooreD., MihatschM.J., GudatF., WaldmanF.: p53 and erbB-2 protein overexpression are associated with early invasion and metastases in bladder cancer. Virchows Archiv. [Pathol.Anat.], 423: 329–334, 1993.
20.
MussH.B., ThorA.D., BerryD.A., KuteT., LiuE.T., Koer-nerF., CirrincioneC.T., BudmanD.R., WoodW.C., BarcosM., HendersonI.C.: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.N. Engl. J. Med., 330: 1260–1266, 1993.
21.
OlumiA.F., TsaiY.C., NicholsP.W., SkinnerD.G., CainD.R., BenderL.I., JonesP.A.: Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder.Cancer Res., 50: 7081–7083, 1990.
22.
PetoR., PikeM.C., ArmitageP., BreslowN.E., CoxD.R., HowardS.V., MantelN., McPhersonK., PetoJ., SmithP.G.: Design and analysis of randomized trials requiring prolonged observation of each patient.II. Br. J. Cancer, 35: 1–35, 1977.
23.
PrestiJ.C., ReuterT.G., FairW.R., Cordon-CardoC.: Molecular genetic alterations in superficial and locally advanced human bladder cancer.Cancer Res., 51: 5405–5409, 1991.
24.
SarkisA.S., BajorinD.F., ReuterV.E., HerrH.W., NettoG., ZhangZ.F., SchultzP.K., Cordon-CardoC., ScherH.: Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant M-VAC.J. Clin. Oncol., 13: 1384–1390, 1995.
25.
SarkisA.S., Cordon-CardoC., ReuterV.R., HerrH.W., ZhangZ-F., MelamedJ., SchultzP., BarjorinD., FairW.R., ScherH.I.: p53 overexpression in patients with invasive bladder cancer treated with neoadjuvant methotrexate, vinblastine, adriamycin, and cisplatin (M-VAC).Proc. Am. Soc. Clin. Oncol., 12: 249, 1993.
26.
SarkisA.S., DalbagniG., Cordon-CardoC., MelamedJ., ZhangZ.F., SheinfeldJ., FairW.R., HerrH.W., ReuterV.E.: Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder.J. Urol., 152: 388–392, 1994.
27.
SarkisA.S., DalbagniG., Cordon-CardoC., ZhangZ.F., SheinfeldJ., FairW.R., HerrH.W., ReuterV.E.: Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.J. Natl. Cancer Inst., 85: 53–59, 1993.
28.
ScherH.I.: Chemotherapy for invasive bladder cancer: neoadjuvant versus adjuvant.Semin. Oncol., 17: 555–565, 1990.
29.
SchultzP., HerrH.W., ZhangZ.F., BajorinD.F., SeidmanA.D., SarkisA.S., FairW.R., ScherrD., BoslG.J., ScherH.I.: Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up.J. Clin. Oncol., 12: 1394–1401, 1994.
30.
SidranskyD., Von EschenbachA., TsaiY.C., JonesP.A., SummerhayesI., MarshallF., PaulM., GreenP., HamiltonS.R., FrostP., VolgelsteinB.: Identification of p53 gene mutations in bladder cancers and urine samples.Science, 252: 706–709, 1991.
31.
SkinnerD.G., DanielsJ.R., RussellC.A., LieskovskyG., BoydS.D., NicholsP., KernW., SakamotoJ., KrailoM., GroshenS.: The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial.J. Urol.145: 459–467, 1991.
32.
SolowayM.S.: Selecting initial therapy for bladder cancer.Cancer, 60: 502–513, 1987.
33.
SplinterT.A.W., Pavone-MacalusoP., JacqminD., RobertsJ.T., CarpentierP., De PauwM., SylvesterR.: A European Organization for Research and Treatment of Cancer-Genitourinary Group phase 2 study of chemotherapy in stage T3-4N0-XM0 transitional cell cancer of the bladder: evaluation of clinical response.J. Urol., 148: 1793–1796, 1992.
34.
StöckleM., MeyenburgW., WellekS., VogesG., GertenbachU., ThüroffJ.W., HuberC.H., HohenfellnerR.: Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy: results of a controlled prospective study.J. Urol., 148: 302–307, 1992.
35.
StöckleM., MeyenburgW., WellekS., VogesG.E., RossmannM., GertenbachU., ThüroffJ.W., HuberC., HohenfellnerR.: Adjuvant polychemotherapy of nonoıgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.J. Urol., 153: 47–52, 1995.
36.
VetJ.A., BringuerP.P., PoddigheP.J., KarthausH.F., De-bruyneF.M., SchalkenJ.A.: p53 mutations have no additional prognostic value over stage in bladder cancer.Br. J. Cancer, 70: 496–500, 1994.
37.
WrightC., MellonK., JohnstonP., LaneD.P., HarrisA.L., HomeC.H.W., NealD.E.: Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder.Br. J. Cancer, 63: 967–970, 1991.
